Regeneron Pharmaceuticals Analysts Recommendations and Consensus

REGN -- USA Stock  

Quarterly Earning Report: November 5, 2019  

The current analyst and expert consensus on Regeneron Pharmaceuticals is Hold with 10 hold recommendations. The current projected target price consensus is 397.27 with 15 analysts opinions. One of the most common ways Regeneron Pharmaceuticals analysists use to provide buy or sell recommendation to public are conference calls analysis and financial statements evaluations. Some experts can also talk to Regeneron Pharmaceuticals vendors, executives, and/or customers. Regeneron Pharmaceuticals recommendation module provides expert sentiment on the projected Regeneron Pharmaceuticals target price to derive its highest and lowest estimates based on target price standard deviation of 45.796. Additionally take a look at Macroaxis Advice on Regeneron Pharmaceuticals to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the prospective of investor risk tolerance and investment horizon.

Regeneron Pharmaceuticals Target Price Consensus

Number of Opinions18
Lowered Outlook0
Raized Outlook0
Hold
Macroaxis Recommendation   Exposure   Valuation

Regeneron Pharmaceuticals Target Price Projection

Current Price

Regeneron Pharmaceuticals Market Quote

Low Price299.94Odds
High Price302.71Odds

301.57

Target Price

Analyst Consensus On Target Price

Low Estimate325.0Odds
High Estimate480.0Odds
Number of Analysts15
Standard Deviation45.796

397.266

Regeneron Pharmaceuticals Analysit Ratings

Average Consensus

Search macroaxis.com